Works about OSIMERTINIB

Results: 322

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.

Published in:

NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00337-w

By:

Criscione, Steven W.;
Martin, Matthew J.;
Oien, Derek B.;
Gorthi, Aparna;
Miragaia, Ricardo J.;
Zhang, Jingwen;
Chen, Huawei;
Karl, Daniel L.;
Mendler, Kerrin;
Markovets, Aleksandra;
Gagrica, Sladjana;
Delpuech, Oona;
Dry, Jonathan R.;
Grondine, Michael;
Hattersley, Maureen M.;
Urosevic, Jelena;
Floc'h, Nicolas;
Drew, Lisa;
Yao, Yi;
Smith, Paul D.

Publication type:

Article

Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cells.

Published in:

Cell Death Discovery, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41420-023-01632-6

By:

Hu, Lulu;
Shi, Ji;
Shen, Dachuan;
Zhai, Xingyue;
Liang, Dapeng;
Wang, Jing;
Xie, Chunrui;
Xia, Zhiyu;
Cui, Jing;
Liu, Feng;
Du, Sha;
Meng, Songshu;
Piao, Haozhe

Publication type:

Article

From ICU to long survival.

Published in:

Oncolog-Hematolog, 2024, n. 69, p. 37

By:

Muntenaşu, Ana-Maria;
Cârlan, Ioana-Roxana;
Cojocaru, Eva-Maria

Publication type:

Article

Prolonged survival in EGFR-mutant lung adenocarcinoma: the power of targeted and combination therapies.

Published in:

Oncolog-Hematolog, 2024, n. 69, p. 33

By:

Grigore, Alina-Lavinia

Publication type:

Article

Zebrafish Xenograft Model of Human Lung Cancer for Evaluating Osimertinib Resistance.

Published in:

BioMed Research International, 2019, p. 1, doi. 10.1155/2019/3129748

By:

Li, Xin-ying;
Huang, Li-tang;
Wu, Jia-qi;
He, Ming-fang;
Zhu, Su-hua;
Zhan, Ping;
Lv, Tang-feng;
Song, Yong

Publication type:

Article

Cancer/testis antigen CAGE mediates osimertinib resistance in non-small cell lung cancer cells and predicts poor prognosis in patients with pulmonary adenocarcinoma.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-43124-8

By:

Yeon, Minjeong;
Lee, Hankyu;
Yeo, Jeongseon;
Jeong, Myeong Seon;
Jung, Hyun Suk;
Lee, Hyerim;
Shim, Kyeonghee;
Jo, Hyein;
Jeon, Doyong;
Koh, Jaemoon;
Jeoung, Dooil

Publication type:

Article

Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States.

Published in:

Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1300183

By:

Gengwei Huo;
Ying Song;
Wenjie Liu;
Xuchen Cao;
Peng Chen

Publication type:

Article

Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach.

Published in:

Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1363259

By:

Feng Liang;
Yimei Zhang;
Qian Xue;
Na Yao

Publication type:

Article

Corrigendum: Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels.

Published in:

Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1242042

By:

Peiwen Li;
Xiaohui Tian;
Gongxin Wang;
Enshe Jiang;
Yanming Li;
Guoliang Hao

Publication type:

Article

Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels.

Published in:

Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1177003

By:

Peiwen Li;
Xiaohui Tian;
Gongxin Wang;
Enshe Jiang;
Yanming Li;
Guoliang Hao

Publication type:

Article

Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels.

Published in:

Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1177003

By:

Peiwen Li;
Xiaohui Tian;
Gongxin Wang;
Enshe Jiang;
Yanming Li;
Guoliang Hao

Publication type:

Article

Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer.

Published in:

Journal of Chinese Pharmaceutical Sciences, 2021, v. 30, n. 3, p. 253, doi. 10.5246/jcps.2021.03.021

By:

Shaohong Luo;
Liangliang Dong;
Yiyuan Li;
Dan Xu;
Min Chen

Publication type:

Article

MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 41, doi. 10.2147/LCTT.S453974

By:

Brazel, Danielle;
Nagasaka, Misako

Publication type:

Article

Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib.

Published in:

Lung Cancer: Targets & Therapy, 2023, v. 14, p. 79, doi. 10.2147/LCTT.S431252

By:

Wang, Li;
Quan, Fei;
Guo, Zhen;
Lu, Zhongyu;
Yang, Duoxia;
Shi, Meiqi

Publication type:

Article

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib.

Published in:

Lung Cancer: Targets & Therapy, 2022, v. 13, p. 23, doi. 10.2147/LCTT.S358902

By:

Zhang, Shannon S;
Ou, Sai-Hong Ignatius

Publication type:

Article

Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non--Small Cell Lung Cancer: Updated Analysis of the RESET Study.

Published in:

Cancer Research & Treatment, 2023, v. 55, n. 4, p. 1152, doi. 10.4143/crt.2023.493

By:

Taeyun Kim;
Tae Won Jang;
Chang Min Choi;
Mi-Hyun Kim;
Sung Yong Lee;
Yoon Soo Chang;
Kye Young Lee;
Seung Joon Kim;
Sei Hoon Yang;
Jeong Seon Ryu;
Jeong Eun Lee;
Shin Yup Lee;
Chan Kwon Park;
Sang Hoon Lee;
Seung Hun Jang;
Seong Hoon Yoon;
Hyung-Joo Oh

Publication type:

Article

Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer.

Published in:

Cancer Research & Treatment, 2023, v. 55, n. 1, p. 112, doi. 10.4143/crt.2022.381

By:

Jang Ho Lee;
Eun Young Kim;
Cheol-Kyu Park;
Shin Yup Lee;
Min Ki Lee;
Seong-Hoon Yoon;
Jeong Eun Lee;
Sang Hoon Lee;
Seung Joon Kim;
Sung Yong Lee;
Jun Hyeok Lim;
Tae-Won Jang;
Seung Hun Jang;
Kye Young Lee;
Seung Hyeun Lee;
Sei Hoon Yang;
Dong Won Park;
Chan Kwon Park;
Hye Seon Kang;
Chang Dong Yeo

Publication type:

Article

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI.

Published in:

Cancer Research & Treatment, 2023, v. 55, n. 1, p. 344, doi. 10.4143/crt.2021.1603

By:

Hye Ryeon Kim;
Hyunji Jo;
Hongsik Kim;
Joohyun Hong;
Sehhoon Park;
Hyun Ae Jung;
Se-Hoon Lee;
Jin-Seok Ahn;
Myung-Ju Ahn

Publication type:

Article

A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1.

Published in:

Cancer Research & Treatment, 2021, v. 53, n. 1, p. 93, doi. 10.4143/crt.2020.459

By:

Cheol-Kyu Park;
Hyun-Ju Cho;
Yoo-Duk Choi;
In-Jae Oh;
Young-Chul Kim

Publication type:

Article

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.

Published in:

Cancer Research & Treatment, 2020, v. 52, n. 1, p. 284, doi. 10.4143/crt.2019.200

By:

Myung-Ju Ahn;
Ji-Youn Han;
Dong-Wan Kim;
Byoung Chul Cho;
Jin-Hyoung Kang;
Sang-We Kim;
James Chih-Hsin Yang;
Tetsuya Mitsudomi;
Jong Seok Lee

Publication type:

Article

Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment.

Published in:

Cancer Research & Treatment, 2018, v. 50, n. 4, p. 1164, doi. 10.4143/crt.2017.460

By:

Jeng-Sen Tseng;
Tsung-Ying Yang;
Kun-Chieh Chen;
Kuo-Hsuan Hsu;
Yen-Hsiang Huang;
Kang-Yi Su;
Sung-Liang Yu;
Gee-Chen Chang

Publication type:

Article

Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer.

Published in:

Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-39139-4

By:

Zhao, Shen;
Zhuang, Wu;
Han, Baohui;
Song, Zhengbo;
Guo, Wei;
Luo, Feng;
Wu, Lin;
Hu, Yi;
Wang, Huijuan;
Dong, Xiaorong;
Jiang, Da;
Wang, Mingxia;
Miao, Liyun;
Wang, Qian;
Zhang, Junping;
Fu, Zhenming;
Huang, Yihua;
Xu, Chunwei;
Hu, Longyu;
Li, Lei

Publication type:

Article

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.

Published in:

2023

By:

Chmielecki, Juliann;
Gray, Jhanelle E.;
Cheng, Ying;
Ohe, Yuichiro;
Imamura, Fumio;
Cho, Byoung Chul;
Lin, Meng-Chih;
Majem, Margarita;
Shah, Riyaz;
Rukazenkov, Yuri;
Todd, Alexander;
Markovets, Aleksandra;
Barrett, J. Carl;
Hartmaier, Ryan J.;
Ramalingam, Suresh S.

Publication type:

Correction Notice

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.

Published in:

Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01391-4

By:

Fu, Kai;
Xie, Fachao;
Wang, Fang;
Fu, Liwu

Publication type:

Article

Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.

Published in:

Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-021-01186-z

By:

Quintanal-Villalonga, Alvaro;
Taniguchi, Hirokazu;
Zhan, Yingqian A.;
Hasan, Maysun M.;
Chavan, Shweta S.;
Meng, Fanli;
Uddin, Fathema;
Allaj, Viola;
Manoj, Parvathy;
Shah, Nisargbhai S.;
Chan, Joseph M.;
Ciampricotti, Metamia;
Chow, Andrew;
Offin, Michael;
Ray-Kirton, Jordana;
Egger, Jacklynn D.;
Bhanot, Umesh K.;
Linkov, Irina;
Asher, Marina;
Roehrl, Michael H.

Publication type:

Article

Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.

Published in:

PLoS ONE, 2024, v. 19, n. 5, p. 1, doi. 10.1371/journal.pone.0303046

By:

Chang, Gee-Chen;
Shih, Jin-Yuan;
Yu, Chong-Jen;
Chao, Heng-Sheng;
Yang, Cheng-Ta;
Lin, Chien-Chung;
Hung, Jen-Yu;
Hsiao, Sheng-Yen;
Wang, Chin-Chou;
Chian, Chih-Feng;
Hsia, Te-Chun;
Chen, Yuh-Min

Publication type:

Article

Adverse Events in Osimertinib Treatment for EGFR-Mutated Non-Small-Cell Lung Cancer: Unveiling Rare Life-Threatening Myelosuppression.

Published in:

Medicina (1010660X), 2024, v. 60, n. 8, p. 1270, doi. 10.3390/medicina60081270

By:

Shalata, Walid;
Abu Jama, Ashraf;
Dudnik, Yulia;
Abu Saleh, Omar;
Shalata, Sondos;
Tourkey, Lena;
Sheva, Kim;
Meirovitz, Amichay;
Yakobson, Alexander

Publication type:

Article

Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report.

Published in:

2022

By:

Kano, Yukari;
Kataoka, Nobutaka;
Kunimatsu, Yusuke;
Tsutsumi, Rei;
Sato, Izumi;
Tanimura, Mai;
Nakano, Takayuki;
Tanimura, Keiko;
Takeda, Takayuki

Publication type:

Case Study

Successful Management of Osimertinib-Induced Heart Failure.

Published in:

Medicina (1010660X), 2022, v. 58, n. 2, p. 312, doi. 10.3390/medicina58020312

By:

Fukuo, Atsuko;
Imamura, Teruhiko;
Onoda, Hiroshi;
Kinugawa, Koichiro

Publication type:

Article

Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.

Published in:

BMC Cancer, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12885-021-08581-2

By:

Wang, Xia;
Cai, Jing;
Zeng, Zhimin;
Liu, Anwen

Publication type:

Article

Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.

Published in:

BMC Cancer, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12885-021-08205-9

By:

Jarry, Ulrich;
Bostoën, Mégane;
Pineau, Raphaël;
Chaillot, Laura;
Mennessier, Valentine;
Montagne, Pierre;
Motte, Emilie;
Gournay, Marjorie;
Le Goff, Arnaud;
Guillaudeux, Thierry;
Pedeux, Rémy

Publication type:

Article

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.

Published in:

Molecular Cancer, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12943-021-01307-9

By:

Wu, Shaocong;
Luo, Min;
To, Kenneth K. W.;
Zhang, Jianye;
Su, Chaoyue;
Zhang, Hong;
An, Sainan;
Wang, Fang;
Chen, Da;
Fu, Liwu

Publication type:

Article

Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation‑positive non‑small cell lung cancer: Results from a Phase IV study in India.

Published in:

Indian Journal of Cancer, 2022, v. 59, p. S1, doi. 10.4103/ijc.ijc_1374_21

By:

Malik, Prabhat S.;
Noronha, Vanita;
Dabkara, Deepak;
Maddu, Vamshi K.;
Rajappa, Senthil;
Limaye, Sewanti;
Batra, Ullas

Publication type:

Article

Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS.

Published in:

Molecules, 2022, v. 27, n. 14, p. N.PAG, doi. 10.3390/molecules27144474

By:

Li, Ying;
Meng, Lu;
Ma, Yinling;
Li, Yajing;
Xing, Xiaoqing;
Guo, Caihui;
Dong, Zhanjun

Publication type:

Article

Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR.

Published in:

Molecules, 2021, v. 26, n. 21, p. 6423, doi. 10.3390/molecules26216423

By:

Almalki, Faisal A.;
Shawky, Ahmed M.;
Abdalla, Ashraf N.;
Gouda, Ahmed M.

Publication type:

Article

Liquid Biopsy in EGFR -Mutated Advanced NSCLC from T790M to MET Amplification: Clinical Implications and Possibilities in the Resistance Setting.

Published in:

Journal of Molecular Pathology, 2023, v. 4, n. 2, p. 81, doi. 10.3390/jmp4020009

By:

Della Gravara, Luigi;
Battiloro, Ciro;
Avellino, Aniello;
Caputo, Francesca;
D'Aniello, Carmine;
Rocco, Danilo

Publication type:

Article

Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study.

Published in:

Biomedicines, 2024, v. 13, n. 7, p. 1412, doi. 10.3390/biomedicines12071412

By:

Fukuda, Shota;
Suda, Kenichi;
Hamada, Akira;
Oiki, Hana;
Ohara, Shuta;
Ito, Masaoki;
Soh, Junichi;
Mitsudomi, Tetsuya;
Tsutani, Yasuhiro

Publication type:

Article

A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety.

Published in:

Biomedicines, 2023, v. 11, n. 9, p. 2501, doi. 10.3390/biomedicines11092501

By:

Fukuhara, Tatsuro;
Imai, Kazuhiro;
Nakagawa, Taku;
Igusa, Ryotaro;
Yokota, Hayato;
Watanabe, Kana;
Suzuki, Aya;
Morita, Mami;
Onodera, Ren;
Inoue, Akira;
Miura, Masatomo;
Minamiya, Yoshihiro;
Maemondo, Makoto

Publication type:

Article

UBL3 Interacts with Alpha-Synuclein in Cells and the Interaction Is Downregulated by the EGFR Pathway Inhibitor Osimertinib.

Published in:

Biomedicines, 2023, v. 11, n. 6, p. 1685, doi. 10.3390/biomedicines11061685

By:

Chen, Bin;
Hasan, Md. Mahmudul;
Zhang, Hengsen;
Zhai, Qing;
Waliullah, A. S. M.;
Ping, Yashuang;
Zhang, Chi;
Oyama, Soho;
Mimi, Mst. Afsana;
Tomochika, Yuna;
Nagashima, Yu;
Nakamura, Tomohiko;
Kahyo, Tomoaki;
Ogawa, Kenji;
Kaneda, Daita;
Yoshida, Minoru;
Setou, Mitsutoshi

Publication type:

Article

PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC).

Published in:

Biomedicines, 2022, v. 10, n. 8, p. N.PAG, doi. 10.3390/biomedicines10081893

By:

Pantazaka, Evangelia;
Ntzifa, Aliki;
Roumeliotou, Argyro;
Lianidou, Evi;
Georgoulias, Vassilis;
Kotsakis, Athanasios;
Kallergi, Galatea

Publication type:

Article

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.

Published in:

Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-91657-7

By:

Huang, Yen-Hsiang;
Tseng, Jeng-Sen;
Hsu, Kuo-Hsuan;
Chen, Kun-Chieh;
Su, Kang-Yi;
Yu, Sung-Liang;
Chen, Jeremy J. W.;
Yang, Tsung-Ying;
Chang, Gee-Chen

Publication type:

Article

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC.

Published in:

Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-89006-9

By:

Tamiya, Motohiro;
Tamiya, Akihiro;
Okamoto, Norio;
Taniguchi, Yoshihiko;
Nishino, Kazumi;
Atagi, Shinji;
Hirashima, Tomonori;
Imamura, Fumio;
Kumagai, Toru;
Suzuki, Hidekazu

Publication type:

Article

Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients.

Published in:

Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-82068-9

By:

Ntzifa, Aliki;
Strati, Areti;
Kallergi, Galatea;
Kotsakis, Athanasios;
Georgoulias, Vassilis;
Lianidou, Evi

Publication type:

Article

Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.

Published in:

Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-67908-4

By:

Li, Xiao-Feng;
Shen, Wei-Zhang;
Jin, Xin;
Ren, Ping;
Zhang, Jie

Publication type:

Article

Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review.

Published in:

Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1188772

By:

Zhiqin Zhang;
Jiamao Lin;
Linke Yang;
Yang Li

Publication type:

Article

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC.

Published in:

Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1182391

By:

Cekay, Michael;
Arndt, Philipp F.;
Dumitrascu, Rio;
Savai, Rajkumar;
Braeuninger, Andreas;
Gattenloehner, Stefan;
Steiner, Dagmar;
Roller, Fritz;
Tello, Khodr;
Hattar, Katja;
Seeger, Werner;
Sibelius, Ulf;
Grimminger, Friedrich;
Eul, Bastian

Publication type:

Article

Long-lasting benefit on multimodal treatment combining osimertinib and stereotaxic radiotherapy for metastatic non-small cell lung cancer with the EGFR exon 20 insertion 773-774 HVdelinsLM: a case report.

Published in:

Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1143775

By:

Louvet, Aurélie;
Honoré, Natasha;
Dekairelle, Anne-France;
Van Marcke, Cédric;
Goeminne, Jean-Charles

Publication type:

Article

Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy.

Published in:: Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1236311
Publication type:: Article

Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer.

Published in:

Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1108124

By:

Pina, Pamela Soberanis;
Lara-Mejía, Luis;
Matias-Cruz, Venecia;
Barrón, Feliciano;
Cardona, Andrés F.;
Raez, Luis E.;
Rios-Garcia, Eduardo;
Arrieta, Oscar

Publication type:

Article

Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib.

Published in:

Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1124949

By:

Kian, Waleed;
Krayim, Bilal;
Alsana, Hadel;
Giles, Betsy;
Purim, Ofer;
Alguayn, Wafeek;
Alguayn, Farouq;
Peled, Nir;
Roisman, Laila C.

Publication type:

Article